OMER Stock Analysis: Omeros | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 681m USD | 12M Return: 235.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.7M
Qual. Beats: 1
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Omeros Corporation is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, founded in 1994 and listed on NASDAQ. The company focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for orphan indications, particularly within immunologic diseases. As a clinical-stage company with no approved products on the market, Omeros relies on external financing and capital markets to fund its research and development activities.
The companys lead product candidate is narsoplimab (OMS721), a MASP-2 inhibitor being developed for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA) and currently in Phase II trials for COVID-19-related acute respiratory distress syndrome. Its pipeline also includes OMS1029, which has completed Phase I trials targeting lectin pathway disorders, and OMS527, which is in Phase I trials for addictions, compulsive disorders, movement disorders, and cocaine use disorder.
Omeros is additionally advancing several preclinical programs, including MASP-2-directed therapeutics for lectin pathway disorders, MASP-3 small-molecule inhibitors for alternative pathway disorders, OncotoX-AML for acute myeloid leukemia, and a Targeted Complement Activating Therapy aimed at multidrug-resistant organisms. The companys focus on orphan indications positions its candidates to benefit from regulatory pathways that provide extended market exclusivity, fee waivers, and tax credits for therapies targeting rare diseases.
- Narsoplimab FDA approval and commercial launch in TA-TMA indication
- Phase III narsoplimab IgA nephropathy trial data readout
- Cash burn raises dilutive financing risk amid pipeline development
| Net Income: 86.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.31 > 0.02 and ΔFCF/TA 96.59 > 1.0 |
| NWC/Revenue: 1.22k% < 20% (prev 3.15k%; Δ -1.92k% < -1%) |
| CFO/TA -0.33 > 3% & CFO -94.8m > Net Income 86.2m |
| Net Debt (187.3m) to EBITDA (92.9m): 2.02 < 3 |
| Current Ratio: 3.03 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.5m) vs 12m ago 9.39% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 3.80% > 50% (prev 0.18%; Δ 3.62% > 0%) |
| Interest Coverage Ratio: 3.29 > 6 (EBIT TTM 92.0m / Interest Expense TTM 28.0m) |
| A: 0.42 (Total Current Assets 180.4m - Total Current Liabilities 59.4m) / Total Assets 286.2m |
| B: -3.00 (Retained Earnings -857.6m / Total Assets 286.2m) |
| C: 0.35 (EBIT TTM 92.0m / Avg Total Assets 260.7m) |
| D: -0.18 (Book Value of Equity -63.3m / Total Liabilities 349.5m) |
| Altman-Z'' = -4.82 = D |
| DSRI: 0.28 (Receivables 37.5m/5.63m, Revenue 9.89m/412k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.64 (AQ_t 0.33 / AQ_t-1 0.52) |
| SGI: 24.01 (Revenue 9.89m / 412k) |
| TATA: 0.63 (NI 86.2m - CFO -94.8m) / TA 286.2m) |
| Beneish M = 12.73 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 10.33 with a total of 1,210,182 shares traded. Over the past week, the price has changed by +4.24%, over one month by +4.87%, over three months by -5.92% and over the past year by +235.39%.
Current recommended Stop Loss: 9.30 (which is 10% or 1.1 ATR below the current price).
Omeros has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy OMER.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 33 | 219.5% |
P/E Trailing = 8.2544
P/E Forward = 58.1395
P/S = 68.8418
P/B = 8.4414
P/EG = 0.8053
Revenue TTM = 9.89m USD
EBIT TTM = 92.0m USD
EBITDA TTM = 92.9m USD
Long Term Debt = 136.8m USD (from longTermDebt, last quarter)
Short Term Debt = 26.3m USD (from shortTermDebt, last quarter)
Debt = 322.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 12.0m
Net Debt = 187.3m USD (calculated: Debt 322.6m - CCE 135.3m)
Enterprise Value = 868.4m USD (681.1m + Debt 322.6m - CCE 135.3m)
Interest Coverage Ratio = 3.29 (Ebit TTM 92.0m / Interest Expense TTM 28.0m)
EV/FCF = 9.91x (Enterprise Value 868.4m / FCF TTM 87.6m)
FCF Yield = 10.09% (FCF TTM 87.6m / Enterprise Value 868.4m)
FCF Margin = 885.9% (FCF TTM 87.6m / Revenue TTM 9.89m)
Net Margin = 871.0% (Net Income TTM 86.2m / Revenue TTM 9.89m)
Gross Margin = unknown ((Revenue TTM 9.89m - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 3.03 (Enterprise Value 868.4m / Total Assets 286.2m)
Interest Expense / Debt = 8.68% (Interest Expense 28.0m / Debt 322.6m)
Taxrate = 0.11% (57.0k / 51.3m)
NOPAT = 91.9m (EBIT 92.0m * (1 - 0.11%))
Current Ratio = 2.78 (Total Current Assets 180.4m / Total Current Liabilities 64.8m)
Debt / Equity = -5.09 (negative equity) (Debt 322.6m / totalStockholderEquity, last quarter -63.3m)
Debt / EBITDA = 2.02 (Net Debt 187.3m / EBITDA 92.9m)
Debt / FCF = 2.14 (Net Debt 187.3m / FCF TTM 87.6m)
Total Stockholder Equity = -158.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 33.06% (Net Income 86.2m / Total Assets 286.2m)
RoE = -54.39% (negative equity) (Net Income TTM 86.2m / Total Stockholder Equity -158.4m)
RoCE = -425.9% (out of range, set to none) (EBIT 92.0m / Capital Employed (Equity -158.4m + L.T.Debt 136.8m))
RoIC = 36.39% (NOPAT 91.9m / Invested Capital 252.5m)
WACC = 9.16% (E(681.1m)/V(1.00b) * Re(9.40%) + D(322.6m)/V(1.00b) * Rd(8.68%) * (1-Tc(0.00)))
Discount Rate = 9.40% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 35.96 | Cagr: 1.71%
[DCF] Terminal Value 72.63% ; FCFF base≈87.6m ; Y1≈88.0m ; Y5≈93.2m
[DCF] Fair Price = 15.01 (EV 1.27b - Net Debt 187.3m = Equity 1.09b / Shares 72.4m; r=9.16% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 4.0 | # QB: 1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.27 | Chg30d=+205.65% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.27 | Chg30d=-37.26% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=0.38 | Chg30d=-10.23% | Revisions=+0% | GrowthEPS=-81.9% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.15 | Chg30d=-128.70% | Revisions=-25% | GrowthEPS=-140.8% | GrowthRev=+111.0%
[Analyst] Revisions Ratio: +17% (up=2, down=1)